InvestorsHub Logo
Followers 196
Posts 24866
Boards Moderated 0
Alias Born 04/03/2010

Re: wimike post# 485525

Saturday, 06/11/2022 4:12:28 AM

Saturday, June 11, 2022 4:12:28 AM

Post# of 709751
It is a PD-1 checkpoint inhibitor for a target group for which use of such a drug works spectacularly. I expect that having snubbed these doctors, all the other checkpoint inhibitor drug providers like Merck, BMS, etc., will jump into that space.

It is a trial for a very specific subgroup with a very specific biomarker/genetic marker for that disease, not all of the patients with that disease but like 5% of the patients with that form of cancer.

It’s also owned now by GlaxoSmithKline. No significant boost in share price from these stories. Despite the news, the share price had been basically flat for the last 6 months.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News